We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$632M
AUM Growth
-$12.8M
Cap. Flow
+$278K
Cap. Flow %
0.04%
Top 10 Hldgs %
85.21%
Holding
32
New
4
Increased
11
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$25.8M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$15.9M
3
CYTK icon
Cytokinetics
CYTK
+$7.39M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$6.41M
5
ACHV icon
Achieve Life Sciences
ACHV
+$4.82M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$13.2M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$10M
3
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$4.05M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$1.43M
5
PTN
Palatin Technologies
PTN
+$1.37M

Sector Composition

Rank Sector Weight
1 Healthcare 86.28%
2 Miscellaneous 13.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VXRT
26
DELISTED
Vaxart
VXRT
$1.24M 0.2%
39,627
– –
PRTK
27
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$299K 0.05%
12,500
– –
AMGN icon
28
PUT
Amgen
AMGN
$203B
– –
-365,400
Closed -$45.1M
RIGL icon
29
Rigel Pharmaceuticals
RIGL
$831M
– –
-257,671
Closed -$10M
MRTX
30
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-74,900
Closed -$1.43M
1
2

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q2 2014 Portfolio in Review

As of Q2 2014, BVF Inc held 32 positions worth $632M, down 2% from $645M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

BVF Inc's Q2 2014 filing shows 4 new, 11 increased, 4 reduced and 3 closed positions. Its largest new stake was Achieve Life Sciences: 392 shares worth $3.22M. The largest sale was Ligand Pharmaceuticals, an estimated $13.2M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier, followed by Miscellaneous.

  • BVF Inc's largest Q2 2014 buy was Achieve Life Sciences: 392 shares worth $3.22M.
  • BVF Inc added most to Array Biopharma Inc in Q2 2014, an estimated $25.8M increase.
  • BVF Inc's biggest Q2 2014 reduction was Ligand Pharmaceuticals, cutting an estimated $13.2M.
  • BVF Inc fully exited Rigel Pharmaceuticals in Q2 2014, selling an estimated $10M.
  • BVF Inc's ten largest holdings make up 85% of its $632M portfolio in Q2 2014.
  • BVF Inc opened 4 new positions and closed 3 in Q2 2014.
  • BVF Inc's portfolio value fell 2% quarter-over-quarter to $632M.

Based on BVF Inc's 13F filing for Q2 2014, filed 14 Aug 2014.